New licensed treatment for Type 2 Diabetes launched in the UK with Cardiovascular Outcomes Evidence

Vipidia (alogliptin) is a new DPP-4i for the management of Type 2 diabetes, launched in the UK with CV safety outcomes.1 Vipidia and the fixed dose combination product Vipdomet® (alogliptin and metformin) are now available in the UK. Vipidia is licensed for the treatment of Type 2 diabetes mellitus in adults aged 18 years and older to improve glycaemic control in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.2

The granting of the licence by the European Medicines Agency (EMA) is based on the results of a robust clinical trial programme including over 14,800 patients.1,2

Full Article

<-- Vitamin D deficiency occurs in an early stage in type 1 diabetes

Genetic mutations discovered that could prevent type 2 diabetes -->